Bio Industry Warns UK Orkambi Inquiry Against Publishing Confidential Price Information
Executive Summary
Vertex and bioindustry groups have called on a UK inquiry investigating the availability of the cystic fibrosis drug Orkambi on the National Health Service not to publish confidential information.
You may also be interested in...
UK Has Sought Advice On Compulsory Licensing For Vertex’ Orkambi
Pressure on Vertex over access to its cystic fibrosis drug Orkambi in England is mounting after the parliamentary undersecretary for health admitted the government has already taken advice on compulsory licensing of the product.
UK Inquiry Schedules Public Hearing On Availability Of Vertex’s Orkambi
In the next stage of the UK inquiry into the availability of Vertex’s cystic fibrosis drug Orkambi on England’s National Health Service, a public hearing will take place in March.
UK Inquiry Into ‘Unfair’ Orkambi Pricing Risks Pricing Confidentiality
The UK government has criticized Vertex for the company’s approach to pricing its cystic fibrosis drug Orkambi. In the meantime, a parliamentary inquiry that could expose sensitive pricing details moves forward.